Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence
Recruitment status was: Not yet recruiting
Ovarian endometriotic cyst (endometrioma) is one of the most common endometriotic lesions, and conservative laparoscopic surgery is the treatment of choice. However, the recurrence after surgery is common.
As repetitive surgery leads to morbidities and ovarian function decrease, recurrence after surgery frustrates both patients and clinicians. In this aspect, medical treatments have been offered after surgery to prevent or delay the recurrence. Gonadotropin-releasing hormone agonist (GnRHa) is frequently used in women with advanced endometriosis, but the efficacy is rather controversial. On the other hand, it has been demonstrated that oral contraceptives (OCs) could reduce or delay endometrioma recurrence, but data are still limited. Consequently, no one type of postoperative medical therapy has been shown to be superior in reducing the recurrence of endometrioma.
The rationale of postoperative medical therapy is that it could eradicate microscopic lesions which were not found and not treated sufficiently during surgery. Therefore, the maintenance of strongly suppressed condition induced by postoperative GnRHa treatment by addition of OCs could be a promising treatment to prevent the recurrence, but it has not been widely investigated.
We performed this retrospective cohort study to evaluate the efficacy of cyclic monophasic low-dose OCs as a maintenance therapy after GnRHa treatment for the suppression of endometrioma recurrence.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Efficacy of Postoperative Cyclic Oral Contraceptive Use After Gonadotropin-releasing Hormone Agonist for the Prevention of Endometrioma Recurrence|
- recurrence rate of endometrioma [ Time Frame: 60 months ]
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||March 2010|
|Estimated Primary Completion Date:||March 2010 (Final data collection date for primary outcome measure)|
OC use after postoperative gonadotropin-releasing hormone agonist treatment
Only postoperative gonadotropin-releasing hormone agonist treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT01092494
|Contact: DooSeok Choi, MD, PhDfirstname.lastname@example.org|
|Korea, Republic of|
|Samsung Medical Center||Not yet recruiting|
|Seoul, Korea, Republic of, 135-710|
|Contact: DooSeok Choi email@example.com|
|Study Director:||DooSeok Choi||Samsung Medical Center|